Koch E, Wiemann H, Empl I
MMW Munch Med Wochenschr. 1980 Mar 21;122(12):431-4.
Cefazedone (Refosporin) was tested for efficacy and tolerance in 1161 patients. The trial was interrupted or unsuitable for evaluation in 54 cases. Diagnostical characteristics of the remaining 1107 patients tested for tolerance were: therapeutical and prophylactic use in surgery (37,5%) infections of the bronchial tract (30.8%), infections of the urogenital tract (17.9%), infections of the abdominocystic tract (6.2%), other infections (7,6%). Of the 1085 patients tested for efficacy--in 22 cases the trial was interrupted because of undesired side effects (exanthema, nausea, local intolerance)--87% concerned exclusively antibiotic therapy with cefazedone. Cefazedone was administered only twice daily i. v. Combined medication with other antibiotics--mainly amino glycosides--was highly efficient.
对1161例患者进行了头孢唑酮(瑞福孢菌素)的疗效和耐受性测试。有54例试验中断或不适合评估。其余1107例接受耐受性测试患者的诊断特征为:外科治疗和预防用药(37.5%)、支气管感染(30.8%)、泌尿生殖道感染(17.9%)、腹囊肿感染(6.2%)、其他感染(7.6%)。在1085例接受疗效测试的患者中,有22例因出现不良副作用(皮疹、恶心、局部不耐受)而中断试验,其中87%仅涉及头孢唑酮抗生素治疗。头孢唑酮仅静脉注射,每日两次。与其他抗生素(主要是氨基糖苷类)联合用药效果显著。